CYTK Cytokinetics, Incorporated - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 6, 2026
$65.60
· of 52w range
· above low
· to high
$54.3052w low
$88.3152w high
Market Cap
$8.07B
P/E (TTM)
-9.1
EPS (TTM)
$-7.23
Revenue (TTM)
$68M
your badges
52W Range
$54–$88
Analyst Rating
BUY
Price Target
$110
P/E
-9.1
ROE
329.8%
Net Profit Margin
-1321.1%
Your badge strip is empty — pin a metric anywhere on this page.
CYTK Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$65.60
Market Cap
$8.07B
P/E (TTM)
-9.1
EPS (TTM)
$-7.23
Revenue (TTM)
$68M
ROE (TTM)
329.8%
Debt/Equity (MRQ)
-1.6
52W Range
$54–$88
CYTK Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| June 25, 2013 | 1-for-6 | Reverse |
About Cytokinetics, Incorporated - Common Stock Company overview from Wikipedia
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
History
Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998.
Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins. Eventually, the company narrowed its focus to the mechanics of muscle biology. Cytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients with cardiovascular and neuromuscular diseases.
In 2004 the company completed its initial public offering (IPO).
In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, with roles in business development, corporate development and R&D.
In 2013, Cytokinetics finalized a licensing and discovery deal with Astellas to research treatment for muscle weakness and fatigue.
In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions.
Products
Omecamtiv mecarbil is a cardiac muscle activator for the potential treatment of heart failure. In May 2020, omecamtiv mecarbil was granted fast track designation by the FDA for the treatment of chronic HF with reduced ejection fraction. Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times. In June 2013, Cytokinetics and Amgen expanded their licensing deal for omecamtiv mecarbil to include Japan. In November 2020 Amgen elected to terminate the collaboration, effective May 20, 2021, and Cytokinetics regained worldwide rights to develop and commercialize omecamtiv mecarbil.
Reldesemtiv (previously known as CK-2127107) is a next-generation fast skeletal muscle troponin activator (FSTA) that has undergone clinical trials for ALS.
Aficamten (previously known as CK-3773274) is an oral, small-molecule myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM).
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealthcare
industryBiotechnology
employees673
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$88M2016-12-31 → 2025-12-31
EPS$-6.542016-12-31 → 2025-12-31
Free Cash Flow$-535M2016-12-31 → 2025-12-31
Net margin-1321.1%2016-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | CYTK | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -9.15Y avg ≈-12.2 | ≈-12.2 | · | · | |
| P/S | 91.65Y avg ≈323.5 | ≈323.5 | 41.9 | Overvalued | |
| P/B | -12.25Y avg ≈-19.9 | ≈-19.9 | · | · | |
| EV / EBITDA | -13.75Y avg ≈-15.1 | ≈-15.1 | · | · | |
| Price / FCF | -15.15Y avg ≈-16.6 | ≈-16.6 | · | · | |
| Price / Cash Flow | -15.85Y avg ≈-18.3 | ≈-18.3 | · | · | |
| EV / Revenue | 93.55Y avg ≈322.6 | ≈322.6 | · | · | |
| EV / FCF | -15.45Y avg ≈-16.6 | ≈-16.6 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | CYTK | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | -1046.1%5Y avg ≈-2159.0% | ≈-2159.0% | -118.4% | Weak | |
| EBITDA Margin (TTM) | -1027.6%5Y avg ≈-2113.0% | ≈-2113.0% | -118.4% | Weak | |
| Net Profit Margin (TTM) | -1321.1%5Y avg ≈-2357.7% | ≈-2357.7% | -176.2% | Weak | |
| ROA (TTM) | -56.8%5Y avg ≈-47.8% | ≈-47.8% | -22.9% | Weak | |
| ROE (TTM) | 329.8%5Y avg ≈322.1% | ≈322.1% | -13.2% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | CYTK | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | -1.65Y avg ≈-0.4 | ≈-0.4 | 0.3 | Low debt | |
| Current Ratio (MRQ) | 6.75Y avg ≈6.7 | ≈6.7 | 5.9 | In line | |
| Quick Ratio | 0.75Y avg ≈1.1 | ≈1.1 | 3.6 | Low liquidity | |
| Long-Term Debt / Equity (MRQ) | -1.45Y avg ≈-0.3 | ≈-0.3 | · | · | |
| Interest Coverage | -13.45Y avg ≈-14.6 | ≈-14.6 | -7.7 | Low liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | CYTK | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 376.6%5Y avg ≈98.1% | ≈98.1% | · | · | |
| Revenue CAGR 3Y | -2.4%5Y avg ≈-29.0% | ≈-29.0% | · | · | |
| Revenue CAGR 5Y | 9.5% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | CYTK | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.15Y avg ≈0.1 | ≈0.1 | 0.2 | Weak | |
| Receivables Turnover | 5.15Y avg ≈4.8 | ≈4.8 | 5.7 | In line | |
| Revenue / Employee | ≈$130.8K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-4.4%
Next Report
Nov 03, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 5, 2026 | $-1.50 | $-1.67 | 10.4% |
| March 31, 2026 | $-1.67 | $-1.69 | 0.94% | |
| Dec. 31, 2025 | $-1.50 | $-1.49 | -0.97% | |
| Sept. 30, 2025 | $-2.55 | $-1.61 | -58.2% | |
| June 30, 2025 | $-1.12 | $-1.41 | 20.3% | |
| March 31, 2025 | $-1.39 | $-1.41 | 1.4% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| R&D Expense | $416M | $339M | $330M | $241M | $160M | $97M | $86M | $89M | $90M | $60M | $46M | $44M | |
| SG&A Expense | $284M | $215M | $174M | $178M | $97M | $53M | $40M | $31M | $36M | $28M | $20M | $17M | |
| Operating Expenses | $700M | $555M | $504M | $419M | $257M | $150M | $126M | $120M | $127M | $88M | $66M | $62M | |
| Operating Income | $-612M | $-536M | $-496M | $-324M | $-186M | $-94M | $-99M | $-89M | $-113M | $19M | $-37M | $-15M | |
| Interest Expense | $46M | $38M | $28M | $19M | $16M | $16M | $7M | $4M | $3M | $3M | $268.0K | $0 | |
| Interest Income | · | · | · | $11M | $1M | $5M | $4M | $4M | · | $449.0K | $156.0K | $101.0K | |
| Other Non-op | $48M | $52M | $28M | $11M | $331.0K | $5M | $5M | $4M | $3M | $464.0K | $174.0K | $108.0K | |
| Pretax Income | · | · | · | · | · | · | · | $-106M | $-128M | $16M | $-38M | $-15M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| EPS (Basic) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.41 | $-0.97 | $-0.41 | |
| EPS (Diluted) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 | |
| Shares (Basic) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 39,943,000 | 38,814,000 | 35,709,000 | |
| Shares (Diluted) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 42,561,000 | 38,814,000 | 35,709,000 | |
| EBITDA | $-602M | $-527M | $-484M | $-318M | $-184M | $-92M | $-98M | $-88M | $-111M | $19M | $-37M | $-14M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $123M | $95M | $113M | $66M | $113M | $83M | $36M | $42M | $125M | $67M | $65M | $20M | |
| Receivables | $18M | $17M | $1M | $147.0K | $52M | $4M | $5M | $2M | $1M | $24.0K | · | · | |
| Inventory | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $17M | $15M | $12M | $12M | $12M | $6M | $3M | $2M | $4M | $2M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Current Assets | $917M | $1.11B | $628M | $795M | $536M | $474M | $234M | $208M | $274M | $159M | $113M | $131M | |
| PP&E (Net) | $79M | $66M | $69M | $80M | $73M | $13M | $5M | $3M | $4M | $4M | $2M | $2M | |
| PP&E (Gross) | $126M | $103M | $97M | $98M | $89M | $38M | $29M | $27M | $26M | $25M | $23M | $22M | |
| Accum. Depreciation | $47M | $37M | $28M | $17M | $16M | $25M | $24M | $24M | $23M | $21M | $21M | $20M | |
| Other Non-current Assets | $17M | $8M | $8M | $10M | $7M | $6M | · | $300.0K | $429.0K | $200.0K | $200.0K | $200.0K | |
| Total Assets | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Accounts Payable | $22M | $20M | $22M | $26M | $21M | $8M | $8M | $4M | $5M | $4M | $2M | $1M | |
| Accrued Liabilities | $83M | $55M | $43M | $44M | $34M | $19M | $12M | $16M | $17M | $18M | $8M | $5M | |
| Current Liabilities | $202M | $180M | $103M | $85M | $72M | $31M | $26M | $22M | $32M | $33M | $32M | $24M | |
| Capital Leases | $108M | $113M | $120M | $127M | $112M | $440.0K | $2M | $771.0K | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $186.0K | $1M | $4M | $0 | · | $771.0K | $1M | $142.0K | · | · | |
| Total Liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597M | $420M | $301M | $185M | $185M | $76M | $47M | $41M | |
| Long-term Debt | $288M | $620M | $639M | $650M | · | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Total Debt | $288M | $105M | $68M | $64M | $47M | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Common Stock | $123.0K | $118.0K | $102.0K | $94.0K | $84.0K | $70.0K | $59.0K | $55.0K | $54.0K | $41.0K | $40.0K | $39.0K | |
| Paid-in Capital | · | · | · | · | $1.45B | · | · | · | · | · | · | $589M | |
| Retained Earnings | $-3.49B | $-2.70B | $-2.11B | $-1.59B | $-1.21B | $-992M | $-865M | $-743M | $-646M | $-518M | $-535M | $-497M | |
| AOCI | $630.0K | $2M | $-10.0K | $-4M | $-869.0K | $149.0K | $679.0K | $500.0K | $343.0K | $137.0K | $149.0K | $-4.0K | |
| Stockholders' Equity | $-660M | $-135M | $-386M | $-108M | $244M | $113M | $-11M | $26M | $110M | $94M | $69M | $92M | |
| Liabilities + Equity | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Shares Outstanding | 122,943,172 | 118,209,139 | 101,637,922 | 94,833,975 | 84,799,542 | 71,015,183 | 59,172,124 | 54,717,906 | 53,960,832 | 40,646,595 | 39,581,692 | 38,659,738 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $10M | $12M | $6M | $2M | $2M | $1M | $1M | $2M | $741.0K | $589.0K | $490.0K | |
| Stock-based Comp | $112M | $98M | $72M | $48M | $27M | $18M | $11M | $10M | $9M | $7M | $5M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Other Non-cash | $153M | $86M | $28M | $36M | $44M | $117M | $19M | $-6M | $15M | $13M | $37M | $-34M | |
| Operating Cash Flow | $-510M | $-396M | $-414M | $-300M | $-143M | $9M | $-91M | $-101M | $-102M | $37M | $5M | $-45M | |
| CapEx | $25M | $4M | $1M | $11M | $49M | $11M | $3M | $889.0K | $3M | $2M | $562.0K | $1M | |
| Investing Cash Flow | $17M | $-553M | $239M | $-262M | $-148M | $-197M | $-75M | $5M | $-66M | · | · | · | |
| Net Debt Issued | $-11M | $-9M | · | $-48M | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Net Stock Activity | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Financing Cash Flow | $524M | $931M | $221M | $516M | $320M | $234M | $160M | $13M | $226M | · | · | · | |
| Net Change in Cash | $30M | $-18M | $46M | $-45M | $30M | $47M | $-6M | $-83M | $58M | $2M | $45M | $57.0K | |
| Taxes Paid | $0 | $0 | $0 | · | · | · | · | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | |
| Free Cash Flow | $-535M | $-400M | $-416M | $-311M | $-191M | $-2M | $-94M | $-102M | $-105M | $35M | $4M | $-46M | |
| Levered FCF | · | · | · | · | · | · | · | $-106M | $-108M | $33M | · | $-46M |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | -168.3% | -368.0% | -282.3% | -848.3% | 17.6% | -130.5% | -31.4% | |
| Net Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| Pretax Margin | · | · | · | · | · | · | · | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| EBITDA Margin | -683.9% | -2851.1% | -6431.8% | -336.6% | -261.3% | -165.0% | -363.2% | -278.3% | -833.9% | 18.3% | -128.5% | -30.4% | |
| ROA | -55.5% | -53.0% | -57.2% | -41.9% | -31.3% | -30.9% | -48.6% | -42.0% | -55.0% | 11.5% | -30.2% | -13.6% | |
| ROE | 152.7% | 789.8% | 127.6% | 628.0% | -87.4% | -96.8% | 790.0% | -272.5% | -125.2% | 20.2% | -46.7% | -20.0% | |
| ROIC | · | · | · | · | · | · | · | -130.1% | -80.1% | 15.0% | -44.9% | -16.0% |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 | 15.2 | 9.0 | 9.4 | 8.5 | 4.8 | 3.6 | 5.5 | |
| Quick Ratio | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 | 2.8 | 1.6 | 2.0 | 3.9 | 2.0 | 2.1 | 0.8 | |
| Debt / Equity | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.6 | 0.3 | 0.3 | 0.2 | · | |
| LT Debt / Equity | -0.4 | -0.7 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.5 | 0.3 | 0.3 | 0.2 | · | |
| Interest Coverage | -13.4 | -14.2 | -17.5 | -16.7 | -11.3 | -5.9 | -14.9 | -23.4 | -37.6 | 6.9 | · | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.7 | 0.2 | 0.4 | |
| Receivables Turnover | 5.1 | 2.1 | 10.5 | 3.6 | 2.5 | 11.7 | 7.3 | 18.8 | 23.5 | · | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-5.37 | $-1.15 | $-3.80 | $-1.14 | $2.88 | $1.60 | $-0.18 | $0.47 | $2.04 | $2.32 | $1.73 | $2.38 | |
| Revenue / Share | $733.03 | $164.98 | $78.01 | $1053.03 | · | · | · | · | $0.27 | $2.50 | · | · | |
| Cash Flow / Share | $-4246.43 | $-3535.39 | $-4292.54 | $-3334.44 | · | · | · | · | $-2.06 | $0.87 | · | · | |
| Cash / Share | $1.00 | $0.80 | $1.11 | $0.69 | $1.33 | $1.17 | $0.62 | $0.77 | $2.32 | $1.65 | $1.64 | $0.52 | |
| EPS (TTM) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 376.6% | 145.3% | -92.0% | 34.3% | 26.2% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -2.4% | -36.0% | -48.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.5% | · | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| Net Income TTM | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| Market Cap | $7.81B | $5.56B | $8.49B | $4.35B | $3.87B | $1.48B | $628M | $346M | $440M | $494M | $414M | $310M | |
| Enterprise Value | $7.98B | $5.57B | $8.44B | $4.34B | $3.80B | $1.44B | $636M | $346M | $346M | $457M | $364M | · | |
| P/E | -9.7 | -8.9 | -15.3 | -10.6 | -16.3 | -10.5 | · | · | -3.1 | 31.2 | -10.8 | -19.5 | |
| P/S | 88.7 | 301.0 | 1126.9 | 45.9 | 54.9 | 26.4 | 23.4 | 11.0 | 32.9 | 4.6 | 14.4 | 6.6 | |
| P/B | -11.8 | -41.1 | -22.0 | -40.3 | 15.8 | 13.0 | -57.4 | 13.3 | 4.0 | 5.2 | 6.0 | 3.4 | |
| P / Tangible Book | · | · | · | · | 15.8 | 13.0 | · | · | · | · | · | · | |
| P / Cash Flow | -15.3 | -14.0 | -20.5 | -14.5 | -27.1 | 165.0 | -6.9 | -3.4 | -4.3 | 13.4 | 84.8 | -6.9 | |
| P / FCF | -14.6 | -13.9 | -20.4 | -14.0 | -20.2 | -699.7 | -6.7 | -3.4 | -4.2 | 14.0 | 95.8 | -6.7 | |
| EV / EBITDA | -13.2 | -10.6 | -17.4 | -13.6 | -20.6 | -15.6 | -6.5 | -3.9 | -3.1 | 23.5 | -9.9 | · | |
| EV / FCF | -14.9 | -13.9 | -20.3 | -14.0 | -19.9 | -682.3 | -6.8 | -3.4 | -3.3 | 12.9 | 84.1 | · | |
| EV / Revenue | 90.6 | 301.5 | 1121.0 | 45.9 | 54.0 | 25.8 | 23.7 | 11.0 | 25.9 | 4.3 | 12.7 | · | |
| Earnings Yield | -10.3% | -11.2% | -6.5% | -9.4% | -6.1% | -9.5% | · | · | -31.8% | 3.2% | -9.3% | -5.1% |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $19M | $18M | $2M | $67M | $2M | $17M | $463.0K | $249.0K | $835.0K | $2M | $378.0K | $867.0K | $5M | $2M | $3M | |
| R&D Expense | $98M | $96M | $104M | $99M | $110M | $98M | $94M | $85M | $80M | $82M | $85M | $83M | $83M | $79M | $75M | $63M | |
| SG&A Expense | $104M | $105M | $92M | $69M | $66M | $57M | $62M | $57M | $51M | $46M | $44M | $40M | $40M | $50M | $54M | $48M | |
| Operating Expenses | $208M | $203M | $196M | $169M | $178M | $157M | $156M | $141M | $130M | $127M | $129M | $123M | $123M | $129M | $129M | $111M | |
| Operating Income | $-179M | $-184M | $-178M | $-167M | $-112M | $-156M | $-139M | $-141M | $-130M | $-126M | $-127M | $-122M | $-122M | $-124M | $-127M | $-108M | |
| Interest Expense | · | · | $14M | $11M | $11M | · | $9M | $9M | $13M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $4M | |
| Other Non-op | $14M | $11M | $11M | $10M | $13M | $14M | $15M | $17M | $12M | $8M | $8M | $7M | $7M | $6M | $6M | $4M | |
| Net Income | $-199M | $-206M | $-183M | $-306M | $-134M | $-161M | $-150M | $-161M | $-143M | $-136M | $-137M | $-129M | $-129M | $-131M | $-137M | $-142M | |
| EPS (Basic) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| EPS (Diluted) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| Shares (Basic) | 132,086 | 123,273 | · | 119,982 | 119,457 | 118,496 | · | 117,685 | 109,240 | 101,924 | · | 96,071 | 95,755 | 95,164 | · | 93,758 | |
| Shares (Diluted) | 132,086 | 123,273 | · | 119,982 | 119,457 | 118,496 | · | 117,685 | 109,240 | 101,924 | · | 96,071 | 95,755 | 95,164 | · | 93,758 | |
| EBITDA | $-179M | $-180M | · | $-167M | $-112M | $-153M | · | $-141M | $-130M | $-124M | · | $-122M | $-122M | $-123M | · | $-108M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $255M | $130M | $123M | $225M | $75M | $74M | $95M | $47M | $190M | $120M | · | $100M | $69M | $102M | · | $106M | |
| Receivables | $24M | $7M | $18M | $2M | $8M | $2M | $17M | $244.0K | $0 | $834.0K | · | $2M | $985.0K | $1M | · | $2M | |
| Inventory | $380.0K | $154.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $14M | $17M | $13M | $20M | $16M | $15M | $7M | $11M | $19M | · | $20M | $20M | $16M | · | $14M | |
| Current Assets | $1.21B | $839M | $917M | $977M | $887M | $956M | $1.11B | $1.02B | $1.07B | $639M | · | $561M | $587M | $681M | · | $884M | |
| PP&E (Net) | $79M | $82M | $79M | $76M | $70M | $67M | $66M | $64M | $66M | $68M | · | $76M | $77M | $79M | · | $80M | |
| PP&E (Gross) | · | · | $126M | · | · | · | $103M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $37M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $19M | $18M | $17M | $17M | $15M | $13M | $8M | $8M | $8M | $8M | · | $8M | $8M | $8M | · | · | |
| Total Assets | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Accounts Payable | $21M | $25M | $22M | $22M | $16M | $14M | $20M | $12M | $9M | $13M | · | $14M | $13M | $17M | · | $14M | |
| Accrued Liabilities | $77M | $69M | $83M | $62M | $52M | $43M | $55M | $50M | $40M | $40M | · | $33M | $31M | $36M | · | $40M | |
| Current Liabilities | $181M | $199M | $202M | $142M | $131M | $160M | $180M | $110M | $103M | $89M | · | $78M | $66M | $75M | · | $76M | |
| Capital Leases | $102M | $105M | $108M | $111M | $111M | $113M | $113M | $115M | $117M | $119M | · | $122M | $124M | $125M | · | $114M | |
| Other Non-current Liabilities | · | · | · | $2M | $2M | $3M | · | $0 | $0 | $2.0K | · | $408.0K | $625.0K | $837.0K | · | $1M | |
| Total Liabilities | $2.10B | $2.10B | $2.08B | $1.96B | $1.59B | $1.53B | $1.54B | $1.45B | $1.42B | $1.20B | · | $1.18B | $1.11B | $1.12B | · | $1.09B | |
| Long-term Debt | $276M | $292M | $288M | $1.00B | $610M | $610M | $105M | $620M | $629M | $630M | · | · | · | · | · | · | |
| Total Debt | $276M | $292M | · | $176M | $173M | $105M | · | $105M | $104M | $68M | · | $61M | $62M | $64M | · | $64M | |
| Common Stock | $138.0K | $124.0K | $123.0K | $122.0K | $119.0K | $119.0K | $118.0K | $118.0K | $117.0K | $105.0K | · | $94.0K | $94.0K | $94.0K | · | $93.0K | |
| Retained Earnings | $-3.89B | $-3.69B | $-3.49B | $-3.30B | $-3.00B | $-2.86B | $-2.70B | $-2.55B | $-2.39B | $-2.25B | · | $-1.98B | $-1.85B | $-1.72B | · | $-1.45B | |
| AOCI | $-4M | $-2M | $630.0K | $34.0K | $-158.0K | $2M | $2M | $5M | $-1M | $-539.0K | · | $-874.0K | $-1M | $-2M | · | $-6M | |
| Stockholders' Equity | $-173M | $-827M | $-660M | $-521M | $-369M | $-266M | $-135M | $-14M | $109M | $-396M | $-386M | $-439M | $-333M | $-229M | $-108M | $-16M | |
| Liabilities + Equity | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Shares Outstanding | · | · | 122,943,172 | · | · | · | 118,209,139 | · | · | · | · | · | · | · | · | · |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $36M | $30M | $31M | $31M | $28M | $24M | $26M | $25M | $25M | $22M | $19M | $19M | $19M | $15M | $13M | $13M | |
| Other Non-cash | · | $27M | · | · | · | $4M | · | · | · | $-18M | · | · | · | $-8M | · | · | |
| Operating Cash Flow | $-160M | $-145M | $-143M | $-108M | $-128M | $-132M | $-66M | $-102M | $-99M | $-130M | $-74M | $-96M | $-122M | $-122M | $-98M | $-84M | |
| CapEx | $4M | $6M | $6M | $9M | $4M | $6M | $1M | $701.0K | $2M | $0 | $77.0K | $220.0K | $717.0K | $402.0K | $3M | $6M | |
| Investing Cash Flow | $-507M | $145M | $-71M | $-71M | $53M | $106M | $111M | $-45M | $-652M | $33M | $-81M | $73M | $82M | $165M | $29M | $-292M | |
| Net Debt Issued | · | $-3M | · | · | · | $-3M | · | · | · | $-705.0K | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | · | · | · | $94M | · | · | · | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $94M | · | · | · | · | · | · | |
| Financing Cash Flow | $793M | $8M | $111M | $330M | $79M | $5M | $2M | $3M | $821M | $104M | $169M | $54M | $5M | $-7M | $30M | $389M | |
| Net Change in Cash | $125M | $7M | $-103M | $152M | $2M | $-21M | $48M | $-143M | $70M | $7M | $13M | $31M | $-34M | $36M | $-39M | $13M | |
| Free Cash Flow | · | $-151M | · | · | · | $-137M | · | · | · | $-130M | · | · | · | $-123M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -626.0% | -948.7% | · | -8613.4% | -167.0% | -9856.3% | · | -30410.6% | -52277.9% | -15118.0% | · | -32345.2% | -14077.2% | -2698.3% | · | -4311.8% | |
| Net Margin | -694.4% | -1064.5% | · | -15815.0% | -201.3% | -10220.1% | · | -34675.0% | -57557.4% | -16244.7% | · | -34238.6% | -14837.0% | -2846.1% | · | -5658.4% | |
| EBITDA Margin | -626.0% | -931.2% | · | -8613.4% | -167.0% | -9710.6% | · | -30410.6% | -52277.9% | -14838.8% | · | -32345.2% | -14077.2% | -2658.2% | · | -4311.8% | |
| ROA | -12.6% | -16.2% | · | -21.3% | -9.8% | -15.6% | · | -14.8% | -12.4% | -16.0% | · | -14.2% | -16.6% | -15.0% | · | -14.9% | |
| ROE | 73.3% | 37.7% | · | 114.5% | 103.3% | 48.7% | · | 70.9% | 127.6% | 43.4% | · | 56.9% | 116.1% | 232.9% | · | -122.1% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.7 | 4.2 | · | 6.9 | 6.8 | 6.0 | · | 9.3 | 10.4 | 7.2 | · | 7.2 | 8.9 | 9.0 | · | 11.6 | |
| Quick Ratio | 1.5 | 0.7 | · | 1.6 | 0.6 | 0.5 | · | 0.4 | 1.9 | 1.4 | · | 1.3 | 1.1 | 1.4 | · | 1.4 | |
| Debt / Equity | -1.6 | -0.4 | · | -0.3 | -0.5 | -0.4 | · | -7.5 | 1.0 | -0.2 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| LT Debt / Equity | -1.4 | -0.3 | · | -0.3 | -0.4 | -0.3 | · | -6.7 | 0.9 | -0.1 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| Interest Coverage | · | · | · | -14.7 | -10.1 | · | · | -15.8 | -10.2 | -17.8 | · | -17.1 | -17.3 | -17.9 | · | -15.9 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.7 | 4.4 | · | 1.9 | 15.9 | 1.1 | · | 0.3 | 0.5 | 0.9 | · | 0.2 | 0.6 | 1.3 | · | 1.7 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $216.71 | $157.01 | · | $16.14 | $558.94 | $13.33 | · | $3.93 | $2.28 | $8.19 | · | $3.93 | $9.05 | $48.47 | · | $26.82 | |
| Cash Flow / Share | · | $-1179.96 | · | · | · | $-1110.73 | · | · | · | $-1270.62 | · | · | · | $-1285.00 | · | · | |
| EPS (TTM) | $-7.23 | $-6.85 | · | $-6.29 | $-5.10 | $-5.29 | · | $-5.38 | $-5.37 | $-5.40 | · | $-5.60 | $-5.77 | $-4.66 | · | $-3.12 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $68M | $106M | · | $87M | $86M | $19M | · | $3M | $3M | $4M | · | $8M | $10M | $98M | · | $148M | |
| Net Income TTM | $-894M | $-830M | · | $-752M | $-606M | $-615M | · | $-576M | $-545M | $-531M | · | $-527M | $-540M | $-431M | · | $-282M | |
| P/E | -11.8 | -9.6 | · | -8.7 | -6.5 | -7.6 | · | -9.8 | -10.1 | -13.0 | · | -5.3 | -5.7 | -7.6 | · | -15.5 | |
| Earnings Yield | -8.5% | -10.4% | · | -11.4% | -15.4% | -13.2% | · | -10.2% | -9.9% | -7.7% | · | -19.0% | -17.7% | -13.2% | · | -6.4% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $88M | $18M | $8M | $95M | $70M |
| Operating Margin % | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% |
| Net Income | $-785M | $-590M | $-526M | $-389M | $-215M |
| Diluted EPS | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debt / Equity | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 |
| Current Ratio | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 |
| Quick Ratio | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-535M | $-400M | $-416M | $-311M | $-191M |
Institutional owners (13F) 535 filers · $13.2B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
535
Value held
$13.2B
New positions
95
Exited positions
49
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 95 (-11 vs prior Q) | 49 (-7 vs prior Q) | 238 (+49 vs prior Q) | 113 (-29 vs prior Q) | +10.8M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| BlackRock, Inc. | $1,711,838,738 | 20,094,362 | 12.99% | Shares |
| VANGUARD GROUP INC | $765,538,243 | 12,048,131 | 5.81% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $590,517,486 | 6,931,770 | 4.48% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $571,778,157 | 6,711,799 | 4.34% | Shares |
| STATE STREET CORP | $553,243,709 | 6,494,233 | 4.20% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $521,151,103 | 6,117,515 | 3.95% | Shares |
| FMR LLC | $428,657,534 | 5,031,782 | 3.25% | Shares |
| Avoro Capital Advisors LLC | $425,949,915 | 4,999,999 | 3.23% | Shares |
| BANK OF AMERICA CORP /DE/ | $394,916,049 | 4,635,709 | 3.00% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $316,325,896 | 3,712,501 | 2.40% | Shares |
| RTW INVESTMENTS, LP | $243,814,036 | 2,862,003 | 1.85% | Shares |
| Polar Capital Holdings Plc | $191,988,358 | 2,253,649 | 1.46% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $161,060,214 | 1,890,600 | 1.22% | Call option |
| GOLDMAN SACHS GROUP INC | $150,069,725 | 1,761,588 | 1.14% | Shares |
| Capital Research Global Investors | $143,683,584 | 1,686,625 | 1.09% | Shares |
| NORTHERN TRUST CORP | $140,337,319 | 1,647,345 | 1.06% | Shares |
| JPMORGAN CHASE & CO | $139,150,046 | 1,588,895 | 1.06% | Shares |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $136,597,224 | 1,603,442 | 1.04% | Shares |
| Integral Health Asset Management, LLC | $136,304,000 | 1,600,000 | 1.03% | Shares |
| Point72 Asset Management, L.P. | $135,257,185 | 1,587,712 | 1.03% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $133,388,883 | 1,565,781 | 1.01% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $131,998,327 | 1,549,458 | 1.00% | Shares |
| ARMISTICE CAPITAL, LLC | $130,340,700 | 1,530,000 | 0.99% | Call option |
| MORGAN STANLEY | $128,664,004 | 1,510,318 | 0.98% | Shares |
| PRINCIPAL FINANCIAL GROUP INC | $111,740,656 | 1,311,664 | 0.85% | Shares |
| Capital International Investors | $111,245,191 | 1,305,848 | 0.84% | Shares |
| Invesco Ltd. | $105,237,167 | 1,235,323 | 0.80% | Shares |
| ARMISTICE CAPITAL, LLC | $102,342,325 | 1,201,342 | 0.78% | Shares |
| UBS Group AG | $99,781,940 | 1,171,287 | 0.76% | Shares |
| Pictet Asset Management Holding SA | $99,038,455 | 1,160,463 | 0.75% | Shares |
| Frazier Life Sciences Management, L.P. | $98,810,092 | 1,159,879 | 0.75% | Shares |
| Bank of New York Mellon Corp | $98,027,901 | 1,150,697 | 0.74% | Shares |
| Holocene Advisors, LP | $97,506,685 | 1,144,579 | 0.74% | Shares |
| Woodline Partners LP | $93,769,315 | 1,100,708 | 0.71% | Shares |
| D. E. Shaw & Co., Inc. | $89,287,894 | 1,048,103 | 0.68% | Shares |
| NORGES BANK | $86,512,319 | 1,015,522 | 0.66% | Shares |
| Royalty Pharma Sub-Manager, LLC | $83,519,594 | 980,392 | 0.63% | Shares |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $81,937,000 | 961,815 | 0.62% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $77,218,175 | 906,423 | 0.59% | Shares |
| CITADEL ADVISORS LLC | $77,062,874 | 904,600 | 0.58% | Call option |
| FRANKLIN RESOURCES INC | $75,911,721 | 891,087 | 0.58% | Shares |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $70,521,134 | 827,810 | 0.53% | Shares |
| Melqart Asset Management (UK) Ltd | $65,385,455 | 767,525 | 0.50% | Shares |
| Siren, L.L.C. | $64,655,121 | 758,952 | 0.49% | Shares |
| Fisher Asset Management, LLC | $63,355,547 | 743,697 | 0.48% | Shares |
| Foresite Capital Management IV, LLC | $60,884,867 | 714,695 | 0.46% | Shares |
| Balyasny Asset Management L.P. | $60,599,821 | 711,349 | 0.46% | Shares |
| Deep Track Capital, LP | $59,633,000 | 700,000 | 0.45% | Shares |
| JANE STREET GROUP, LLC | $59,633,000 | 700,000 | 0.45% | Call option |
| BNP PARIBAS FINANCIAL MARKETS | $58,702,470 | 689,077 | 0.45% | Shares |
Company insiders 52 insiders · 19 officers · 23 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Robert I Blum | President & CEO | Sept. 28, 2026 M | 278,544 | 0 | 20 | $-17,291,957 |
| Sung Lee | EVP, Chief Financial Officer | July 1, 2026 M | 63,221 | 0 | 5 | $-5,695,855 |
| Ching Jaw | SVP Finance & CFO | March 6, 2023 A | 87,346 | 0 | 0 | $0 |
| Sharon Surrey Barbari | EVP, Finance & CFO | Feb. 28, 2017 F | 40,323 | 0 | 0 | $0 |
| Fady Ibraham Malik | EVP Research & Development | Sept. 22, 2026 M | 153,902 | 0 | 21 | $-4,654,735 |
| Andrew Callos | EVP, Chief Commercial Officer | Aug. 31, 2026 M | 58,555 | 0 | 25 | $-16,021,293 |
| Jeffrey Hessekiel | Chief Legal & Admin Officer | March 15, 2026 A | 107,943 | 0 | 0 | $0 |
| Robert Wong | VP, Chief Accounting Officer | Dec. 3, 2024 A | 18,655 | 0 | 0 | $0 |
| Brett A Pletcher | EVP, Chief Legal Officer | Aug. 30, 2024 A | 33,140 | 0 | 0 | $0 |
| Mark A Schlossberg | SVP - Legal & General Counsel | March 15, 2022 M | 103,408 | 0 | 0 | $0 |
| David Cragg | Chief HR & Admin Officer | March 7, 2022 F | 153,233 | 0 | 0 | $0 |
| Caryn Gordon Mcdowell | GC & Chief Compliance Officer | Feb. 27, 2018 A | 32,548 | 0 | 0 | $0 |
| Peter S Roddy | SVP Finance & CAO | Feb. 27, 2018 A | 21,520 | 0 | 0 | $0 |
| Bradley Paul Morgan | SVP Drug Discovery & Early Dev | Aug. 31, 2017 M | 46,441 | 0 | 0 | $0 |
| Bonnie Charpentier | SVP Regulatory & Compliance | Feb. 28, 2017 A | 29,004 | 0 | 0 | $0 |
| Andrew A Wolff | SVP & CMO | Feb. 28, 2017 A | 47,255 | 0 | 0 | $0 |
| David J Morgans JR | EVP-Preclinical R&D | Feb. 28, 2011 A | 42,000 | 0 | 0 | $0 |
| Michael Rabson | SVP Business Dev/Legal & GC | Dec. 18, 2009 M | 20,043 | 0 | 0 | $0 |
| Jay K Trautman | VP, Discovery Research | Feb. 29, 2008 A | 47,896 | 0 | 0 | $0 |
| Robert E Landry | Director | Sept. 15, 2026 S | 8,184 | 0 | 2 | $-146,790 |
| Lynne B Parshall | Director | Sept. 1, 2026 S | 10,784 | 0 | 4 | $-1,357,500 |
| Robert Arthur Harrington | Director | July 15, 2026 A | 21,932 | 0 | 1 | $-143,620 |
| James M Daly | Director | July 15, 2026 A | 3,390 | 0 | 0 | $0 |
| Edward M. Kaye MD | Director | July 15, 2026 A | 10,434 | 0 | 4 | $-2,837,811 |
| Nancy Wysenski | Director | July 15, 2026 A | 33,992 | 0 | 0 | $0 |
| Wendell Wierenga | Director | July 15, 2026 A | 35,563 | 0 | 3 | $-1,881,925 |
| John T Henderson | Director | July 15, 2026 A | 78,360 | 0 | 2 | $-2,078,525 |
| Muna Bhanji | Director | May 27, 2026 A | 26,361 | 0 | 0 | $0 |
| Wendall Wierenga | Director | July 15, 2025 A | 32,345 | 0 | 0 | $0 |
| COSTA SANTO J | Director | May 15, 2024 A | 20,600 | 0 | 0 | $0 |
| Sandford D Smith | Director | Jan. 2, 2024 A | 18,801 | 0 | 0 | $0 |
| Robert Califf | Director | Jan. 3, 2022 A | 6,003 | 0 | 0 | $0 |
| GAGE L PATRICK | Director | Nov. 8, 2021 M | 28,932 | 0 | 0 | $0 |
| Denise Gilbert | Director | May 20, 2015 J | · | 0 | 0 | $0 |
| Stephen M Dow | Director | Jan. 2, 2013 A | 1,421,052 | 0 | 0 | $0 |
| James A Spudich | Director | May 18, 2011 A | 180,600 | 0 | 0 | $0 |
| Grant A Heidrich III | Director | Jan. 3, 2011 A | 93,755 | 0 | 0 | $0 |
| Michael Schmertzler | Director | June 3, 2010 S | 4,340,923 | 0 | 0 | $0 |
| Mark Mcdade | Director | May 21, 2009 A | · | 0 | 0 | $0 |
| Charles J Homcy | Director | May 22, 2008 A | · | 0 | 0 | $0 |
| William J Rutter | Director | April 29, 2004 C | 172,413 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VI LP | 10% owner | April 29, 2004 C | 1,615,716 | 0 | 0 | $0 |
| SRB ASSOCIATES VIII LP | 10% owner | April 29, 2004 C | 771,052 | 0 | 0 | $0 |
| SRB ASSOCIATES VII LP | 10% owner | April 29, 2004 C | 650,000 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VIII LP | 10% owner | April 29, 2004 C | 755,631 | 0 | 0 | $0 |
| Elisabeth Schnieders | · | Feb. 28, 2017 A | 43,919 | 0 | 0 | $0 |
| James H Sabry | · | June 3, 2010 M | 0 | 0 | 0 | $0 |
| SEVIN ROSEN VII AFFILIATES FUND LP | · | April 29, 2004 C | 24,050 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VII LP | · | April 29, 2004 C | 625,950 | 0 | 0 | $0 |
| SRB ASSOCIATES VI LP | · | April 29, 2004 C | 1,742,951 | 0 | 0 | $0 |
| SEVIN ROSEN VIII AFFILIATES FUND LP | · | April 29, 2004 C | 15,421 | 0 | 0 | $0 |
| SEVIN ROSEN VI AFFILIATES FUND LP | · | April 29, 2004 C | 127,235 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 56 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| PTH · Invesco Exchange-Traded Fund Trust | 1.54% | 85,826 SH | Oct. 1, 2026 | Daily |
| BBP · ETFis Series Trust I | 1.51% | 19,346 NS | July 31, 2026 | N-PORT |
| XMMO · Invesco Exchange-Traded Fund Trust | 0.83% | 881,672 SH | Oct. 1, 2026 | Daily |
| LABU · Direxion Shares ETF Trust | 0.79% | 50,312 NS | July 31, 2026 | N-PORT |
| IBB · iShares Trust | 0.73% | 1,020,305 SH | Sept. 11, 2026 | Daily |
| FNY · First Trust Exchange-Traded AlphaDE… | 0.72% | 53,872 NS | July 31, 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0.64% | 107,023 NS | July 31, 2026 | N-PORT |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.64% | 102,933 SH | Aug. 19, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.60% | 9,831 SH | Oct. 1, 2026 | Daily |
| IQSM · New York Life Investments ETF Trust | 0.35% | 14,748 NS | July 31, 2026 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0.34% | 21,280 SH | Oct. 1, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.34% | 761,130 SH | Aug. 19, 2026 | Daily |
| IVOG · VANGUARD ADMIRAL FUNDS | 0.33% | 72,343 SH | Aug. 19, 2026 | Daily |
| RSSL · Global X Funds | 0.33% | 63,327 NS | July 31, 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0.32% | 1,797,986 SH | Aug. 19, 2026 | Daily |
| IVOO · VANGUARD ADMIRAL FUNDS | 0.32% | 219,413 SH | Aug. 19, 2026 | Daily |
| IWM · iShares Trust | 0.32% | 3,378,753 SH | Sept. 11, 2026 | Daily |
| IVOV · VANGUARD ADMIRAL FUNDS | 0.31% | 53,623 SH | Aug. 19, 2026 | Daily |
| ISCG · iShares Trust | 0.30% | 39,366 SH | Sept. 11, 2026 | Daily |
| PTMC · Pacer Funds Trust | 0.29% | 14,892 NS | July 31, 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0.27% | 48,364 NS | July 31, 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0.24% | 20,179 NS | July 31, 2026 | N-PORT |
| ESML · iShares Trust | 0.23% | 88,671 SH | Sept. 11, 2026 | Daily |
| MIDU · Direxion Shares ETF Trust | 0.22% | 1,994 NS | July 31, 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0.22% | 687 NS | July 31, 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.22% | 16,176 NS | July 31, 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0.21% | 54,306 NS | July 31, 2026 | N-PORT |
| FFLG · FIDELITY COVINGTON TRUST | 0.20% | 15,469 NS | July 31, 2026 | N-PORT |
| SMDX · Tidal Trust III | 0.19% | 3,254 NS | July 31, 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0.17% | 40,586 SH | Aug. 19, 2026 | Daily |
| VB · VANGUARD INDEX FUNDS | 0.14% | 3,113,794 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.14% | 333,056 SH | Aug. 19, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.13% | 1,557,779 SH | Aug. 19, 2026 | Daily |
| FHLC · FIDELITY COVINGTON TRUST | 0.12% | 52,671 NS | July 31, 2026 | N-PORT |
| ESSC · Strategy Shares | 0.10% | 466 NS | July 31, 2026 | N-PORT |
| WSML · iShares Trust | 0.09% | 7,841 SH | Sept. 11, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.07% | 15,233 SH | Aug. 19, 2026 | Daily |
| IWO · iShares Trust | 0.07% | 133,196 SH | Sept. 11, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.07% | 27,790 SH | Oct. 1, 2026 | Daily |
| TILT · FlexShares Trust | 0.02% | 5,740 NS | July 31, 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.02% | 4,315,260 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.02% | 10,880 SH | Aug. 19, 2026 | Daily |
| ESGV · VANGUARD WORLD FUND | 0.02% | 29,174 SH | Aug. 19, 2026 | Daily |
| IUSG · iShares Trust | 0.01% | 64,511 SH | Sept. 11, 2026 | Daily |
| IUSV · iShares Trust | 0.01% | 53,197 SH | Sept. 11, 2026 | Daily |
| ITOT · iShares Trust | 0.01% | 180,021 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.01% | 36,083 SH | Sept. 10, 2026 | Daily |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.01% | 106,638 SH | Aug. 19, 2026 | Daily |
| RWK · Invesco Exchange-Traded Fund Trust … | 0.00% | 478 SH | Sept. 29, 2026 | Daily |
| IJH · iShares Trust | · | 4,763,860 SH | Sept. 11, 2026 | Daily |
| IJK · iShares Trust | · | 425,186 SH | Sept. 11, 2026 | Daily |
| IJJ · iShares Trust | · | 318,457 SH | Aug. 21, 2026 | Daily |
| IWN · iShares Trust | · | 1,107,696 SH | Sept. 11, 2026 | Daily |
| XJH · iShares Trust | · | 18,548 SH | Sept. 8, 2026 | Daily |
| ISCB · iShares Trust | · | 5,565 SH | Sept. 11, 2026 | Daily |
| SMLF · iShares Trust | · | 71,881 SH | Sept. 11, 2026 | Daily |
CYTK Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 28 analysts
BUY
Median target
$107.50
+63.9%
6 21.4%
Strong Buy
19 67.9%
Buy
3 10.7%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
20 analysts · 2026-09-29Mean target $109.90 +67.5%
← Below all targets
Current price $65.60
Low$85.00
Mean$109.90
High$146.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | · |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | · |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | · |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | · |
| PTGX | $5.47B | -42.6 | -89.4% | -282.8% | -20.3% | · |
| PCVX | $6.05B | -8.2 | · | · | -26.6% | · |
| TGTX | $4.63B | 10.8 | 87.3% | 72.6% | 96.7% | · |
| SYRE | $2.56B | 10.1 | -62.0% | · | -26.5% | · |
| PRAX | $7.43B | -21.9 | 249.5% | · | -47.3% | · |
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 6, 2026